Gilead Sciences (GILD) Equity Average (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Equity Average data on file, last reported at $23.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 20.6% year-over-year to $23.1 billion; the trailing twelve-month figure through Mar 2026 stood at $23.1 billion (up 20.6% YoY), and the FY2025 full-year result was $21.0 billion, changed 0.11% from the prior year.
• Equity Average for Q1 2026 stood at $23.1 billion, up from $22.1 billion in the prior quarter.
• Across five years, Equity Average topped out at $23.1 billion in Q1 2026 and bottomed at $17.8 billion in Q2 2024.
• The 5-year median for Equity Average is $20.6 billion (2025), against an average of $20.5 billion.
• The widest annual swing landed in 2024, when Equity Average declined 16.35%; it then gained 20.6% in 2026.
• A 5-year view of Equity Average shows it stood at $21.1 billion in 2022, then gained by 6.45% to $22.5 billion in 2023, then retreated by 16.35% to $18.8 billion in 2024, then increased by 17.56% to $22.1 billion in 2025, then advanced by 4.46% to $23.1 billion in 2026.
• The last three Equity Average figures came in at $23.1 billion (Q1 2026), $22.1 billion (Q4 2025), and $20.6 billion (Q3 2025), per Business Quant data.

Peer Comparison